Category: BÜHLMANN Calprotectin Assay Citations

Turbidimetric Determination of Fecal Calprotectin Using Two Table Top Chemistry Analyzers: Mindray BS-200E and Cobas® c111

BÜHLMANN fCAL® turbo: Mandic-Havelka, A. Nilsen, T. et. al. Turbidimetric Determination of Fecal Calprotectin Using Two Table Top Chemistry Analyzers: Mindray BS-200E and Cobas® c111.  Clin Lab.  2017 May 1;63(5):907-913. doi: 10.7754/Clin.Lab.2016.161032.  PMID: 28627817 Highlights from this Publication “The assay was linear in the range between 20 and 1,900 µg/g with a limit of quantification around 20
Continue Reading

Agreement Between Home-based Measurement of Stool Calprotectin and ELISA Results for Monitoring Inflammatory Bowel Disease Activity

IBDoc® Citation: Heida A, Knol M, Kobold AM, Bootsman J, Dijkstra G, van Rheenen PF, Agreement Between Home-based Measurement of Stool Calprotectin and ELISA Results for Monitoring Inflammatory Bowel Disease Activity, Clinical Gastroenterology and Hepatology (2017) Jun 9. pii: S1542-3565(17)30712-7. DOI:10.1016/j.cgh.2017.06.007,  PMID:28606846. Highlights from this Publication “… we showed that the smartphone reader used by patients
Continue Reading

Usability of a Home-Based Test for the Measurement of Fecal Calprotectin in Asymptomatic IBD Patients Digestive and Liver Disease

IBDoc® Citation: Bello C, Roseth A, Guardiola J, Reenaers C, Ruiz-Cerulla A, Kemseke C Van, Arajol C, Reinhard C, Seidel L, Louis E.Usability of a home-based test for the measurement of fecal calprotectin in asymptomatic IBD patients. Digestive and Liver Disease. 2017 May 19. pii: S1590-8658(17)30886-1. http://dx.doi.org/10.1016/j.dld.2017.05.009 PMID: 28587751 Highlights from this Publication “ …Globally, the correlation between
Continue Reading

Validation of a Care Pathway for the Use of Faecal Calprotectin in Monitoring Patients with Crohn’s Disease

BÜHLMANN fCAL® ELISA Citation: Turvill J, Rook L, Rawle M, et al. Validation of a care pathway for the use of faecal calprotectin in monitoring patients with Crohn's disease. Frontline Gastroenterology Published Online First: 30 January 2017. doi: 10.1136/flgastro-2016-100780. Highlights from this Publication “In patients with Crohn’s Disease, established on therapy, fecal calprotectin effectively identifies those who
Continue Reading

The Utility of Fecal Calprotectin in the Real-World Clinical Care of Patients with Inflammatory Bowel Disease

BÜHLMANN Quantum Blue® fCAL Citation: Abej, E. et al. The Utility of Fecal Calprotectin in the Real-World Clinical Care of Patients with Inflammatory BowelDisease Can J Gastroenterol Hepatol. 2016;2016:2483261. Epub 2016 Sep 28.DOI:10.1155/2016/2483261.  PMID: 27774443.  This Canadian study represents how FCAL testing is utilized in the field for monitoring disease activity in IBD.  The reference for the cut-off
Continue Reading

Proactive Therapeutic Drug Monitoring of Infliximab: A Comparative Study of a New Point-of-Care Quantitative Test with Two Established ELISA Assays

BÜHLMANN Quantum Blue® Infliximab Trough Level Assay Citation: Afonso J, Lopes S et al. Proactive therapeutic drug monitoring of infliximab: a comparative study of a new point-of-care quantitative test with two established ELISA assays. Aliment Pharmacol Ther. 2016 Oct;44(7):684-92. doi: 10.1111/apt.13757. Epub 2016 Aug 10. PMID: 27507790 First Publication using our Quantum Blue® Infliximab Trough Level Assay We are very
Continue Reading

FOCUS: Future of Fecal Calprotectin Utility Study in Inflammatory Bowel Disease

BÜHLMANN Quantum Blue® fCAL Citation: Rosenfeld G, Greenup A-J, Round A, et al. FOCUS: Future of fecal calprotectin utility study in inflammatory bowel disease. World Journal of Gastroenterology. 2016;22(36):8211-8218. doi:10.3748/wjg.v22.i36.8211. PMID:27688663. Highlight from this Publication "The FC test effected a change in management 51.3% of the time and receipt of the result was associated with a reduction
Continue Reading

A Novel Turbidimetric Immunoassay for Fecal Calprotectin Optimized for Routine Chemistry Analyzers

BÜHLMANN fCAL® turbo Citation: Nilsen, T. et. al.  A novel turbidimetric immunoassay for fecal calprotectin optimized for routine chemistry analyzers. J Clin Lab Anal. 2016 Sep 15. PMID:27629827 The publication describes the technical performance of the turbidimetric assay on the cobas c501 and the Mindray BS-380. Highlight from this Publication Short assay time of 10 min with
Continue Reading

Fecal Calprotectin in Healthy Children Aged 1-4 Years

BÜHLMANN fCAL® ELISA Citation: Zhu, Q,Feng Li, Junli Wang, Lixiao Shen, Xiaoyang Sheng. Fecal Calprotectin in Healthy Children Aged 1-4 Years, PLOS ONE. 2016. http://dx.doi.org/10.1371/journal.pone.0150725. “Children aged from 1 to 4 years old have lower FC concentrations compared with healthy infants (<1years), and higher FC concentrations when comparing with children older than 4 years and adults.” Learn More
Continue Reading

Comparison of Three Tests for Faecal Calprotectin in Children and Young Aults: a Retrospective Monocentric Study

BÜHLMANN fCAL® ELISA Citation Prell, C, Nagel D, Freudenberg H, Schwarzer A, Koletzko S. Comparison of three tests for faecal calprotectin in children and young adults: a retrospective monocentric study, BMJ Open. 2014;4:e004558 doi:10.1136/bmjopen-2013-004558. “In conclusion, measurement of FC in paediatric patients with unspecific symptoms is very helpful in order to avoid invasive procedure.” Highlights from this Publication “In conclusion, measurement
Continue Reading
Sign Up for BUHLMANN Updates!

Enter your email and stay on top of things,